Free Trial

Eyenovia Q4 2023 Earnings Report

Eyenovia logo
$0.96 -0.15 (-13.50%)
As of 03:58 PM Eastern

Eyenovia EPS Results

Actual EPS
-$13.60
Consensus EPS
-$13.60
Beat/Miss
Met Expectations
One Year Ago EPS
-$13.60

Eyenovia Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eyenovia Announcement Details

Quarter
Q4 2023
Time
After Market Closes
Remove Ads

Eyenovia Earnings Headlines

Eyenovia enters non-binding LOI to effect reverse merger with Betaliq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks
Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.”
See More Eyenovia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eyenovia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyenovia and other key companies, straight to your email.

About Eyenovia

Eyenovia (NASDAQ:EYEN), an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Eyenovia Profile

More Earnings Resources from MarketBeat